In the immunogenic Panc02-SIY tumor model, antibody therapy increased SIY-specific CD8+ T cells but the addition of peritumoral DR-BMCs did not further augment the therapy (Fig. 3b). The gene discussed is CD8A; the disease is neoplasm.